Altman Advisors Inc. acquired a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 13,369 shares of the biopharmaceutical company’s stock, valued at approximately $1,599,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Bender Robert & Associates lifted its stake in Alexion Pharmaceuticals by 1.3% in the fourth quarter. Bender Robert & Associates now owns 32,873 shares of the biopharmaceutical company’s stock valued at $3,931,000 after buying an additional 430 shares during the last quarter. Verity Asset Management Inc. raised its stake in shares of Alexion Pharmaceuticals by 20.9% during the fourth quarter. Verity Asset Management Inc. now owns 2,626 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 454 shares during the last quarter. Reliance Trust Co. of Delaware raised its stake in shares of Alexion Pharmaceuticals by 9.2% during the fourth quarter. Reliance Trust Co. of Delaware now owns 5,747 shares of the biopharmaceutical company’s stock worth $687,000 after purchasing an additional 482 shares during the last quarter. Amalgamated Bank raised its stake in shares of Alexion Pharmaceuticals by 2.0% during the third quarter. Amalgamated Bank now owns 26,086 shares of the biopharmaceutical company’s stock worth $3,660,000 after purchasing an additional 518 shares during the last quarter. Finally, Standard Life Aberdeen plc raised its stake in shares of Alexion Pharmaceuticals by 1.1% during the fourth quarter. Standard Life Aberdeen plc now owns 49,041 shares of the biopharmaceutical company’s stock worth $5,866,000 after purchasing an additional 526 shares during the last quarter. Institutional investors own 95.34% of the company’s stock.
Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $122.03 on Tuesday. The stock has a market capitalization of $28,098.12, a price-to-earnings ratio of 62.26, a price-to-earnings-growth ratio of 1.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. Alexion Pharmaceuticals’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 earnings per share. equities analysts expect that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current fiscal year.
ALXN has been the subject of several analyst reports. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Zacks Investment Research cut Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Morgan Stanley upped their price target on Alexion Pharmaceuticals from $148.00 to $151.00 and gave the stock an “overweight” rating in a research note on Friday, February 9th. Credit Suisse Group restated a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Raymond James Financial restated an “outperform” rating and set a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twenty-one have assigned a buy rating to the stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $155.22.
In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 1,625 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $119.83, for a total value of $194,723.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the sale, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. Insiders sold 31,253 shares of company stock worth $3,656,229 in the last three months. 4.35% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Altman Advisors Inc. Takes $1.60 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://ledgergazette.com/2018/03/20/altman-advisors-inc-takes-1-60-million-position-in-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.